期刊文献+

区域缓释化疗在乳腺癌改良根治术中的应用 被引量:3

Application of regional sustained-release chemotherapy to modified radical mastectomy of breast cancer
下载PDF
导出
摘要 目的探讨乳腺癌改良根治术使用缓释型氟尿嘧啶对预防术后局部复发的价值。方法将28例乳腺浸润性导管癌患者随机分为2组,其中治疗组13例,在乳腺癌改良根治术结束后,直视下于手术区域撒布缓释型氟尿嘧啶500 mg;对照组15例,除不使用缓释型氟尿嘧啶外,其他处理同治疗组。结果经中位随访27个月,治疗组没有发现局部复发,对照组有4例出现局部复发,二者之间差异显著(χ2=4.044,P<0.05)。结论缓释型氟尿嘧啶手术区域使用有助于预防乳腺癌术后局部复发,提高乳腺癌综合疗效。 Objective To explore the value of applying sustained - release fluorouracil to the modified radical mastectomy of breast cancer in the prevention of postoperative local relapse. Methods Twenty eight patients with mammary gland infiltrating ductal carcinoma were randomly divided into two groups. Treatment group had 13 cases which received 500 mg fluorouracil spread to the tumor bed region after modified radical mastectomy. Control group had 15 cases which received the same treatment as the former group did except that with sustained - release fluorouracil. Results After 27 months of median follow - up, no local relapse was found in the treatment group. There were 4 cases of local relapse in the control group. There were significant differences in the rate of local relapse between the two groups (χ^2 = 4. 044, P 〈 0.05 ). Conclusion It is useful to apply sustained - release fluorouracil to the operative region for the prevention of local relapse after modified radical mastectomy and the improvement of the comprehensive curative effects on the breast cancer.
出处 《西南国防医药》 CAS 2013年第4期355-357,共3页 Medical Journal of National Defending Forces in Southwest China
基金 四川省科技厅面上项目(2011JYZ044) 成都军区总医院英杰人才工程计划
关键词 乳腺癌 根治术 缓释型氟尿嘧啶 局部复发 breast cancer radical mastectomy sustained - released fluorouracil local relapse
  • 相关文献

参考文献10

二级参考文献66

共引文献119

同被引文献23

  • 1杨倩,朱庆莉,姜玉新,戴晴.乳腺癌改良根治术后局部胸壁复发的临床特征与超声表现[J].中华医学超声杂志(电子版),2013,10(8):656-661. 被引量:8
  • 2张亚,张长乐,黄道林,盛勇,尹情胜,钟国勇.植入用缓释氟尿嘧啶治疗乳腺癌的临床观察[J].安徽医药,2007,11(10):878-879. 被引量:11
  • 3Mersin H, Yildirim E, Berberoglu U, et al. The prognos- tic importancer of triple negative breast carcinoma[J]. Breast, 2008,17 (4) : 341 - 346.
  • 4Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients[J]. Breast Cancer Res Treat, 2008,111 : 27- 44.
  • 5Keam B, Im SA, Kim H J, et al. Prognostic impact of clini- copathologic parameters in stage II/HI breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007,7 : 203.
  • 6Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy inpa- tients with anthracycline and taxane-pretreated meta- static breast cance[J]. Eur J Cancer, 2004,40 : 536 - 542.
  • 7Gelmon K, Dent R, Mackey J, et al. Targeting triplenega- tive breast cancer., optimizing therapeutic outcomes[J]. Ann Oncol, 2012,10 : 1093.
  • 8Sirohi B, Arnedos M, Popat S, et al. Platinum- based chemotherapy in triple-negative breast cancer[J]. Ann Oncol,2008,19(11) :1847-1852.
  • 9Buzder AU, Xu B, Digmarti R, et al. Randomized phase II on-inferiority study of two different doses of eapeeit- abine in eombination with doeetaxel for locally advaeed/ metastatic breast eaeer[J]. Ann Oneol, 2012,23 : 589 - 597.
  • 10Lumachi F, Basso SM, Santeufemia DA, et al. Ultrasonic dissec- tion system technology in breast cancer: a case-control study in a large cohort of patients requiring axillary dissection [ J ]. Breast Cancer Res Treat,2013,142(2) :399-404.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部